Company / SG&A Expense
ACCENDRA HEALTH INC/VA/ SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$1.1B
FY2025
5-year range
$1.0B / $1.6B
FY2021-FY2025
Trend
-1.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has fluctuated over the past 10 years, ranging from $953M in FY2019 to $1.6B in FY2022.
Based on SEC 10-K filings.
$1.1B in FY2025 with a 5-year CAGR of +0.5%.
Increased from $1.0B to $1.1B over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -11.8%
- 5-Year CAGR
- +0.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +0.5%, indicating consistent growth.
- In FY2025, sg&a expense decreased 1.4% year-over-year.
- Peak sg&a expense was recorded in FY2022.
- Lowest sg&a expense in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.60 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.1B | -1.4% |
| FY2024 | $1.1B | +8.1% |
| FY2023 | $1.0B | -35.6% |
| FY2022 | $1.6B | +52.0% |
| FY2021 | $1.0B | -1.8% |
| FY2020 | $1.0B | +9.3% |
| FY2019 | $952.9M | +0.0% |
| FY2018 | $952.9M | -6.3% |
| FY2017 | $1.0B | +4.8% |
| FY2016 | $970.4M | -2.4% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026